Table 2. COVID-19 treatment during hospitalization.
| Variables | Total, N (%) | ED, N (%) | Non-ED, N (%) | P value |
|---|---|---|---|---|
| COVID-19 diagnosis | 0.17 | |||
| Pneumonia | 63 (41.2) | 44 (69.8) | 19 (31.2) | |
| Pharyngitis | 79 (51.6) | 46 (58.2) | 33 (40.8) | |
| Asymptomatic | 11 (7.2) | 9 (81.8) | 2 (18.2) | |
| Medications | ||||
| Favipiravir | 70 (45.8) | 48 (68.5) | 22 (31.5) | 0.36 |
| Corticosteroids | 36 (23.5) | 24 (66.7) | 12 (33.3) | 0.78 |
| Remdesivir | 10 (6.5) | 9 (90.0) | 1 (10.0) | 0.08 |
| Tocilizumab | 5 (3.3) | 4 (80.0) | 1 (20.0) | 0.47 |
| Oxygen supplement | 20 (13.1) | 15 (75.0) | 5 (25.0) | 0.3 |
ED, erectile dysfunction.